A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q1 FY2025, filed Aug 14, 2024. Each column of the statement tables below links to the filing it was taken from.
This page shows Nascent Biotech Inc (NBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Nascent's 2024 statements show a development-stage business financed externally, with liabilities above assets and operating cash outflows.
In FY2022, a net loss of$470K coexisted with operating cash flow of$413K , showing earnings and cash were then moving differently. By FY2024, operating cash flow was-$1.19M alongside a net loss of$2.09M , making cash funding needs more pronounced than the income statement alone suggests.
FY2024 liabilities of
FY2024 financing cash flow of
Financial Health Signals
We do not publish a peer-relative financial health score for Nascent Biotech Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Nascent Biotech Inc passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Nascent Biotech Inc reported a net loss of $2.1M while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Nascent Biotech Inc reported an operating loss of $2.2M against $385K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Nascent Biotech Inc reported a net loss of $377K in Q1 2025.
Not reported for Q1 2025.
Not reported for Q1 2025.
Not reported for Q1 2025.
Cash & Balance Sheet
Nascent Biotech Inc held $47K in cash as of Q1 2025; no long-term debt figure is on record for that period.
Not reported for Q1 2025.
Not reported for Q1 2025.
Margins & Returns
None of these metrics is reported for Q1 2025.
Capital Allocation
Nascent Biotech Inc invested $15K in research and development in Q1 2025. This represents a decrease of 42.1% from the same quarter a year earlier.
Not reported for Q1 2025.
Not reported for Q1 2025.
NBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | N/A |
| R&D Expenses | $15K-42.1% | N/A | $47K-15.6% | $28K-62.6% | $26K-54.5% | N/A | $56K+36.3% | $76K-10.7% |
| SG&A Expenses | $106K+20.9% | N/A | $102K-23.3% | $82K+0.1% | $88K-20.0% | N/A | $133K+88.5% | $82K+198.6% |
| Operating Income | -$376K | N/A | -$364Kn/m | -$837Kn/m | N/A | N/A | -$475K-175.3% | -$521Kn/m |
| Interest Expense | $2K-99.2% | N/A | $107-100.0% | $125K-54.6% | $238K+239.8% | N/A | $649K+12772.4% | $276K+10389.8% |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m | N/A |
| Net Income | -$377K | N/A | -$205Kn/m | -$829Kn/m | N/A | N/A | -$837K-240.2% | -$146Kn/m |
| EPS (Basic) | N/A | N/A | N/A | N/A | N/A | N/A | -$0.01-200.0% | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | -$0.01-200.0% | N/A |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | N/A | N/A | 120M+6.4% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA.
NBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $227K+188.1% | $552K+116.5% | $641K+13.3% | $1.0M-13.2% | $79K-56.9% | $255K+141.9% | $566K-24.7% | $1.2M+1039.2% |
| Current Assets | $227K+188.1% | $552K+116.5% | $642K+13.4% | $1.0M-13.2% | $79K-56.9% | $255K+141.9% | $566K-24.7% | $1.2M+1039.2% |
| Cash & Equivalents | $47K+399.9% | $372K+116.1% | $624K+11.6% | $1.0M-15.1% | $9K-93.5% | $172K+82.4% | $559K+32068.3% | $1.2M+1054.4% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $742K-37.9% | $809K-47.9% | $611K-68.3% | $1.0M-56.1% | $1.2M-26.3% | $1.6M+99.7% | $1.9M+60.9% | $2.4M+107.6% |
| Current Liabilities | $742K-39.9% | $809K-47.9% | $611K-68.3% | $1.0M-56.1% | $1.2M-23.8% | $1.6M+99.7% | $1.9M+60.9% | $2.4M+107.6% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0n/m | -$40Kn/m | $0n/m | $0n/m | $0n/m |
| Total Equity | -$515Kn/m | -$257Kn/m | $30Kn/m | -$6Kn/m | -$1.1Mn/m | -$1.3Mn/m | -$1.4Mn/m | -$1.2Mn/m |
| Retained Earnings | -$24.6Mn/m | -$24.3Mn/m | -$23.7Mn/m | -$23.5Mn/m | -$22.2Mn/m | -$21.6Mn/m | -$21.1Mn/m | -$20.3Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$325Kn/m | -$352Kn/m | -$330Kn/m | -$342Kn/m | -$163Kn/m | -$387K-232.1% | -$623Kn/m | -$434Kn/m |
| Stock-Based Compensation | $0-100.0% | N/A | N/A | N/A | $6K-90.7% | N/A | N/A | N/A |
| Financing Cash Flow | N/A | $100Kn/m | -$50Kn/m | $1.3M-9.1% | $0-100.0% | $0n/m | $0n/m | $1.5M+1370.0% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
NBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'25Filing | Q4'24Filing | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | -676.4% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -166.0% | N/A | -32.0%+116.0pp | -79.5%-67.4pp | N/A | N/A | -148.0%-227.4pp | -12.1%+188.0pp |
| Current Ratio | 0.31+0.2x | 0.68+0.5x | 1.05+0.8x | 0.99+0.5x | 0.060.0x | 0.160.0x | 0.29-0.3x | 0.50+0.4x |
| Liabilities-to-Equity | N/A | N/A | 20.12 | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | 0.00-1.3x | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$257K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.68), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Nascent Biotech Inc NBIO | FY2024 | N/A | -$2.1M | N/A | $69K | — |
| Vincerx Pharma Inc VINC | FY2024 | N/A | -$30.1M | N/A | $79K | — |
| Sigyn Therapeutics Inc SIGY | FY2024 | N/A | N/A | N/A | $145K | — |
| Ocean Biomedical Inc OCEA | FY2024 | N/A | N/A | N/A | $23K | — |
| CERo Terapeutics Holding Inc CERO | FY2025 | N/A | N/A | N/A | $217K | — |
| Regen BioPharma Inc RGBP | FY2025 | $237K | -$1.3M | N/A | $355K | — |
Where Nascent Biotech Inc Ranks
Frequently Asked Questions
No, Nascent Biotech Inc (NBIO) reported a net loss of $2.1M in fiscal year 2024.
Nascent Biotech Inc (NBIO) recorded an outflow of $1.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
Nascent Biotech Inc (NBIO) had $552K in total assets as of fiscal year 2024, including both current and long-term assets.
Nascent Biotech Inc (NBIO) invested $111K in research and development during fiscal year 2024.
Nascent Biotech Inc (NBIO) had a current ratio of 0.68 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Nascent Biotech Inc (NBIO) had a return on assets of -378.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Nascent Biotech Inc (NBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $69K as of Nov 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Nascent Biotech Inc (NBIO) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $69K as of Nov 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2024, Nascent Biotech Inc (NBIO) held $372K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.2M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Nascent Biotech Inc (NBIO) has negative shareholder equity of -$257K as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Nascent Biotech Inc (NBIO) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Nascent Biotech Inc (NBIO) reported a net loss of $2.1M while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Nascent Biotech Inc (NBIO) reported an operating loss of $2.2M against $385K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.